用于预测急性髓系白血病治疗反应的基因集、方法、产品及应用
By detecting differentiation arrest and promotion gene sets in stem-like malignant cells, a predictive model was constructed, which solved the problem of insufficient accuracy in predicting treatment response in acute myeloid leukemia in existing technologies, and achieved efficient assessment of treatment response and survival prognosis.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HAIHE LAB OF CELL ECOSYSTEM
- Filing Date
- 2026-01-12
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have limited accuracy in predicting treatment response to acute myeloid leukemia (AML), lack effective biomarkers originating from leukemia stem and progenitor cells, and struggle to address the core biological mechanisms of AML resistance and relapse.
A gene set, including a differentiation arrest gene set and a differentiation promotion gene set, is provided for predicting treatment response in acute myeloid leukemia. A predictive model is constructed to predict treatment response by detecting gene expression levels in stem cell-like malignant cells.
It improves the accuracy of treatment response prediction, meets the needs of precision medicine, can be validated in single-cell transcriptome data and batch transcriptome data, and achieves the dual functions of treatment response prediction and survival prognosis assessment. The protocol is easy to standardize.
Smart Images
Figure CN121496061B_ABST